For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...
Backed with $82 million and led by two of BioMarin’s former executives, Mendra plans to acquire rare disease assets and use ...
CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern ...
BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced it has won the ...
FDA and EMA have issued 10 guiding principles for AI in drug development with the intended goal of ensuring safety and ...
Chinese drugmaker Qilu Pharmaceutical will be responsible for developing metabolic disease drug candidates from Insilico Medicine under a contract with a total value that "approaches" $120 million, ...
Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.
Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...
HKeyBio, a preclinical CRO focused on autoimmune and allergic disease drug development, today announced a translational preclinical strategy, HKEY-AIRxTM1.0 designed to address one of the most persis ...
Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that the U.S. Food and Drug Administration has granted orphan drug ...
China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...
Uncover the systematic approach to biotech firm valuation using DCF. Equip yourself with the knowledge to gauge company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results